Elucidation of the Application of Blood Test Biomarkers to Predict Immune-Related Adverse Events in Atezolizumab-Treated NSCLC Patients Using Machine Learning Methods

BACKGROUND: Development of severe immune-related adverse events (irAEs) is a major predicament to stop treatment with immune checkpoint inhibitors, even though tumor progression is suppressed. However, no effective early phase biomarker has been established to predict irAE until now. METHOD: This st...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jian-Guo, Wong, Ada Hang-Heng, Wang, Haitao, Tan, Fangya, Chen, Xiaofei, Jin, Su-Han, He, Si-Si, Shen, Gang, Wang, Yun-Jia, Frey, Benjamin, Fietkau, Rainer, Hecht, Markus, Ma, Hu, Gaipl, Udo S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284319/
https://www.ncbi.nlm.nih.gov/pubmed/35844547
http://dx.doi.org/10.3389/fimmu.2022.862752

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284319/
https://www.ncbi.nlm.nih.gov/pubmed/35844547
http://dx.doi.org/10.3389/fimmu.2022.862752

Ejemplares similares